ResearcherSt. John's UniversityNo recent work listed

Manali Patki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4139-8839; OpenAlex author ID A5050692415. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper

Papers 2

In vitro assessment of a synergistic combination of gemcitabine and zebularine in pancreatic cancer cells. Co-author DOI 10.1016/j.yexcr.2021.112660 ↗
Nanoformulation of PROteolysis TArgeting Chimera targeting 'undruggable' c-Myc for the treatment of pancreatic cancer. First author DOI 10.2217/nnm-2020-0156 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Aishwarya L. Saraswat · 2 shared papers, 2020–2021 · strength 0.31
- Paper In vitro assessment of a synergistic combination of gemcitabine and zebularine in pancreatic cancer cells. DOI 10.1016/j.yexcr.2021.112660 ↗
- Paper Nanoformulation of PROteolysis TArgeting Chimera targeting 'undruggable' c-Myc for the treatment of pancreatic cancer. DOI 10.2217/nnm-2020-0156 ↗
Ketan R. Patel · 2 shared papers, 2020–2021 · strength 0.31
- Paper In vitro assessment of a synergistic combination of gemcitabine and zebularine in pancreatic cancer cells. DOI 10.1016/j.yexcr.2021.112660 ↗
- Paper Nanoformulation of PROteolysis TArgeting Chimera targeting 'undruggable' c-Myc for the treatment of pancreatic cancer. DOI 10.2217/nnm-2020-0156 ↗
Vikas V. Dukhande · 2 shared papers, 2020–2021 · strength 0.31
- Paper In vitro assessment of a synergistic combination of gemcitabine and zebularine in pancreatic cancer cells. DOI 10.1016/j.yexcr.2021.112660 ↗
- Paper Nanoformulation of PROteolysis TArgeting Chimera targeting 'undruggable' c-Myc for the treatment of pancreatic cancer. DOI 10.2217/nnm-2020-0156 ↗
Shraddha P. Bhutkar · 1 shared paper, 2021 · strength 0.17
- Paper In vitro assessment of a synergistic combination of gemcitabine and zebularine in pancreatic cancer cells. DOI 10.1016/j.yexcr.2021.112660 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.